3.8. In vivo pharmacokinetic studyBEST-5 exhibited the shortest in vitro/in vivo disintegration times (<30 s) and faster in vitro dissolution rate (about 72% after 2.5 min). Moreover, it showed optimum bioenhanced absorption through buccal membrane due to the inclusion of Sepitrap™ 80 in its composition. Therefore BEST-5 was selected for the in vivo pharmacokinetic study compared to Zomig-ZMT 2.5 mg orally disintegrating tablets.The mean plasma zolmitriptan concentration versus time curves following sublingual administration of BEST-5 and Zomig®-ZMT to four volunteers is shown in Fig. 6. The mean pharmacokinetic characteristics are summarized in Table 2. The mean Cmax estimated from BEST of zolmitriptan (2.45 ± 0.24 ng/mL) was larger and statistically significantly different (p = 0.02115) relative to the mean from the marketed product (1.82 ± 0.14 ng/mL) and the 90% confidence interval for the test/reference mean ratio of the log-transformed data of Cmax (1.16–1.47) failed to satisfy the bioequivalence criteria. The nonparametric test, Kruskal-Wallis test, was used to compare the medians of Tmax of both test and market products confirming that Tmax of bioenhanced sublingual tablet is smaller and statistically significant different from that of market product. The significant higher value of Cmax and the lower values of Tmax of BEST-5 compared to that of the market product confirm the enhanced absorption of drug from the sublingual mucosa due to the inclusion of Sepitrap™ 80 as a bioenhancer. The rapid absorption of drug from BEST-5 correlates well with the results of ex vivo permeation which showed that zolmitriptan exhibited higher permeation from bioenhanced sublingual tablets than from the market tablet.
การแปล กรุณารอสักครู่..
